Aileens Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Investors
-
3
Aileens Pharma General Information
Description
Developer of non-steroidal drugs designed for the treatment of atopic dermatitis and other skin diseases. The company's treatments challenge the lack of non-pharmacological therapies and focus on creating medicines for atopic dermatitis, seborrheic dermatitis, and psoriasis, enabling doctors and healthcare organizations to take protective measures and treat the symptoms related to skin diseases.
Contact Information
Website
www.aileenspharma.comCorporate Office
- 1 Via Donatori Di Sangue
- Nova Milanese, Lombardia
- 20834 Milan
- Italy
Corporate Office
- 1 Via Donatori Di Sangue
- Nova Milanese, Lombardia
- 20834 Milan
- Italy
Aileens Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 01-Apr-2026 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 18-Jul-2018 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Aileens Pharma Patents
Aileens Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4559469-A1 | Compositions for prevention or treatment of dysbiosis | Inactive | 22-Nov-2023 | ||
| AU-2022276457-A1 | Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production | Pending | 21-May-2021 | ||
| CA-3219681-A1 | Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production | Pending | 21-May-2021 | ||
| EP-4341379-A1 | Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production | Pending | 21-May-2021 | ||
| US-20240238352-A1 | Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production | Pending | 21-May-2021 | A61K35/74 |
Aileens Pharma Signals
Aileens Pharma Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Tech and Biomedical Foundation | Venture Capital | Minority | ||
| CDP Venture Capital (Rome) | Venture Capital | Minority | ||
| Panakes Partners | Venture Capital | Minority |
Aileens Pharma FAQs
-
When was Aileens Pharma founded?
Aileens Pharma was founded in 2018.
-
Where is Aileens Pharma headquartered?
Aileens Pharma is headquartered in Milan, Italy.
-
What is the size of Aileens Pharma?
Aileens Pharma has 4 total employees.
-
What industry is Aileens Pharma in?
Aileens Pharma’s primary industry is Drug Discovery.
-
Is Aileens Pharma a private or public company?
Aileens Pharma is a Private company.
-
What is Aileens Pharma’s current revenue?
The current revenue for Aileens Pharma is .
-
How much funding has Aileens Pharma raised over time?
Aileens Pharma has raised $3.5M.
-
Who are Aileens Pharma’s investors?
Tech and Biomedical Foundation, CDP Venture Capital (Rome), and Panakes Partners have invested in Aileens Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process